New medicine for rare diseases! C3 inhibitor pegcetacoplan received FDA priority review: Phase 3 efficacy beats heavyweight C5 inhibitor Soliris
Time of Update: 2020-11-28
November 18, 2020 // -- Apellis Pharma is a leader in the development of C3 targeted therapies and is committed to pioneering and best-in-class therapies through a ground-breaking targeted C3 approach to treat a wide range of diseases driven
Advanced kidney cancer "immune and targeted" first-line treatment! The Opdivo-Cabometyx combination is on the market in Japan, beating Sutt!
Time of Update: 2020-11-08
(DOR). specific data are: (1) OS, opdivo and Cabometyx group compared to the Sutt group significantly reduced the risk of death by 40% (HR s 0.60; 98.89% CI: 0.40-0.89; p s 0.0010), 2 groups of the middle OS did not reach. (2) study
Chinese medicine industry stands in the spotlight, related equipment industry is expected to meet new opportunities
Time of Update: 2020-11-04
pharmacies are generally equipped with a new type of frying equipment, can be convenient and quick to fry good Chinese medicine, simple and convenient operation, and save time and effort. this year, affected by the special period, the demand
Classic Hodgkin's Lymphoma (cHL) new drug! Mercedon Keytruda is approved by the FDA to beat Adcetris!
Time of Update: 2020-11-02
-drug therapy for second-line treatment of adult patients with recurring or refractic classic Hodgkin's lymphoma (r/r cHL). approval is based on the results of the head-to-head KeyNOTE-204 Test (NCT02684292). data show that in adult
Advanced kidney cancer "immune and targeted" first-line treatment! The Opdivo-Cabometyx program was reviewed by the FDA as a priority, beating Sutt!
Time of Update: 2020-11-01
improvements at all ends of the efficacy, including total lifetime (OS), progress-free lifetime (PFS), objective mitigation rate (ORR), and mitigation duration (DOR). specific data are: (1) OS, opdivo and Cabometyx group compared to the Sutt
New strategy to beat antibiotic resistance! Modular synthesis redesigns existing antibiotic molecules.
Time of Update: 2020-10-25
now, in a new study, researchers at the University of California, San Francisco, are using a different approach to antibiotic resistance: redesigning existing antibiotic molecules to avoid bacterial resistance.
for listing: head-to-head phase 3 efficacy beats heavyweight C5 inhibitor Soliris.
Time of Update: 2020-10-07
16, 2020 // -- Apellis Pharmaceuticals is committed to developing pioneering and best-in-class therapies through a groundbreaking targeted C3 approach to treat a wide range of diseases driven by uncontrolled or overactivated complement cascading reactions, including hematology, ophthalmology and nephrology.
Artificial sweet mix beats "bitterness"
Time of Update: 2020-09-17
Original title: Artificial sweet mixing beats "bitterness People discovered more than 60 years ago that artificial sweeteners such as saccharin and saccharin mixes are better than "single use", but this confusing phenomenon is still hard
A new drug for multiple sclerosis! Novarhua once a month of ofatumab III clinical efficacy beat Sanofi oral drug Aubagio!
Time of Update: 2020-08-27
and safety of of ofatumumab and the potential of the drug as the preferred treatment for RMS patients to continue their lives. of our commitment to advancing scientific development, researching potential treatments, reimagining care
Acta Neuropathol: Gene new therapy beats you to reverse Alzheimer's-related memory loss.
Time of Update: 2020-08-25
, and that number is expected to exceed 150 million by 2050. early stages, AD is characterized by the accumulation and memory loss of amyloid (A beta) and tau proteins in the brain. , however, the current therapeutic effect of targeting beta
Chilling! 10 tons of pork scattered in one place was robbed only 3 tons of cargo owner crash beat.
Time of Update: 2020-08-11
On August 4, an accident involving a truck in Jiangsu Province, where 10 tons of pork was strewn and robbed, leaving only 3 tons, the cargo owner collapsed and filmed a shameless scene crying "Don't take it".
Nat Commun: The reason why the new crown virus is hard to beat has been found! It turns out to mimic the human mRNA "hat structure"
Time of Update: 2020-08-05
virus so hard to eliminate? Recently, Nature Communication published an article entitled "R.R.I.A. by SARS-CoV-2", which answered our questions. the study found that SARS-CoV-2 was able to simulate a person's mRNA modification process to "disguise
Treatment of type 2 diabetes! Lilly Trulicity efficacy beats somarutide and essenatide.
Time of Update: 2020-08-01
Original source: Once-weekly Trulicity ® (dulaglutide) sturly highly er and more persistence to-weekly semaglutide and exenatide injections source: GLP-1RA sugar-lowering drug real-world research: Lilly Trulicity (dulaglutide) compliance/persistence
How to develop a universal vaccine that beats COVID, SARS, MERS and the common cold!
Time of Update: 2020-07-28
Similar tests have shown that antibodies that cause the antibodies in the part of the stingprotein domain can cross-react with the resulting virus.
"Heart-brained"? The Allen Institute found that when the heart beats, the brain shakes, revealing
Time of Update: 2020-07-22
The brain shakes when the heart beats, and the researchers used this movement to better understand different types of neurons. . In a study published March 11 in Cell Reports, a journal of Cell Press Cell Press, researchers found
Asthma Innovative Triple Therapy! Novartis LABA/LAMA/ICS ProductEnerzair Breezhaler III Clinical Efficacy Beats Shulidi!
Time of Update: 2020-07-17
in other secondary endpoint analyses, Enerzzair Breezhaler improved lung function, significantly reduced the acute exacerbation rate of moderate and severe asthma compared to a mature LABA/ICS standard (Sametero/profloxate fluoricalones(Advair, Shuriadi, high dose Sal/Flu (50/500?g) 2 times a day).
Classic Hodgkin's lymphoma (cHL) new drug! Mercadon Keytruda was reviewed by the FDA as a priority, and the efficacy beats Adcetris!
Time of Update: 2020-07-10
, July 10, 2020 / PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has accepted a new supplemental biologics licensing application (sBLA) for anti-PD-1 therapy Keytruda (Corrida, generic name: pemzumalib, Paboli Zhusinga
Fosun Pharma, medicine Ming Kant again shot! These innovation companies will be in the spotlight by 2020
Time of Update: 2020-07-09
New Element Almedicine was founded in 2012 and is mainly engaged in the development of innovative drugs for metabolic diseases and anti-cancer drugs, including 7 innovative drugs for the treatment of gout, hyperuric acidemia, non-alcoholic
UCB Psoriasis New Drug Beats Stelara
Time of Update: 2020-07-09
on 13, UCB announced its two stage 3 clinical results of IL-17A/F antibody bimekizumab at the annual meeting of the American Association of Dermatology. The two trials, called BE VIVID and BE READY, were compared with placebo and Johnson
New psoriasis drug! Uber's IL-17A/17F double inhibitor bimekizumab Phase III Project Success: Efficacy Beats Johnson and Johnson Stelara (Sidano)
Time of Update: 2020-06-26
, June 15, 2020 /
Biovalley BIOON/UCB recently announced for the first time data on the clinical development program of the new anti-inflammatory drug bimekizumab for the treatment of moderate to severe chronic serifoid psycosis III